Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
The Company continues expansion of its lumateperone programs with the advancement of a Long-Acting injectable formulation into clinical trials.
Intra-Cellular Therapies: Another Growth Cycle Approaching
01:33pm, Friday, 04'th Dec 2020
After a magnificent performance last year with Caplyta approval for schizophrenia, Intra-Cellular stocks gave up some gains. And it's been trading in cyclical growth spurts of gives and takes. Investo
2 Underrated Biotech Stocks to Buy Now
05:32am, Tuesday, 01'st Dec 2020
These two biotech companies are safe bargains in today's volatile market.
Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference
08:00am, Monday, 30'th Nov 2020
NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript
03:01pm, Monday, 09'th Nov 2020
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q3 2020 Results - Earnings Call Transcript
Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
07:30am, Monday, 09'th Nov 2020
P ositive topline results reported from Study ‘402, a Phase 3 Study evaluating lumateperone as an adjunctive treatment to lithium or valproate in patients with bipolar depression.
Got $1,000? You Could Double Your Money by Investing in These 2 Biotechs
07:04am, Saturday, 07'th Nov 2020
Innovation might be worth the high risk up front investment.
Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast
08:00am, Wednesday, 04'th Nov 2020
NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central ne
Intra-Cellular Therapies: Navigating Choppy CNS Treatment Waters With Aplomb (NASDAQ:ITCI)
10:36pm, Wednesday, 30'th Sep 2020
Intra-Cellular won approval for Schizophrenia treatment Caplyta in Dec 2019 after a protracted review by the FDA.
Sep 30, 2020 (The Expresswire) --
Global Paediatric Neuropsychiatric Disorders Treatment Market Report tracks the major market events including product...
Enhanced Healthcare Partners Announces Investment in NeuroPsychiatric Hospitals
12:00am, Wednesday, 30'th Sep 2020
Enhanced Healthcare Partners (“EHP”), a leading healthcare-focused private equity firm specializing in middle-market healthcare services businesses, i
Notable Insider Buys of the Past Week: Nikola, Transdigm And More
12:00am, Sunday, 20'th Sep 2020
Insider buying can be an encouraging signal for potential investors when markets are near all-time highs.
One beneficial owner took advantage of secondary offerings at...
Intra-Cellular Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
03:14am, Saturday, 12'th Sep 2020
Intra-Cellular stock jumps as its bipolar trial delivers positive data. Medtronic moves ahead with heart valve disease trial.
Intra-Cellular Therapies Inc (ITCI) Q2 2020 Earnings Call Transcript
09:30pm, Monday, 10'th Aug 2020
Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer, Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer, Mark Neumann, Executive Vice President a
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Misses Revenue Estimates
12:45pm, Monday, 10'th Aug 2020
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -2.13% and -37.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
